Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells
Apr
20
2023
On demand

Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells

NK cells are effector lymphocytes of the innate immune system that control several types of tumors and microbial infections by limiting their spread and subsequent tissue damage. Genetically engineered primary human NK cells for clinical immuno-oncology applications hold great promise due to their potent antitumor properties and demonstrated safety in an allogeneic setting.

One of the key challenges faced by the cell therapy industry is the expansion and editing of NK cells using conventional methods. In this presentation, we will discuss how various cell therapy products developed by Thermo Fisher Scientific, including the Cell Therapy Systems™ (CTS) Xenon™ Electroporation System and CTS TrueCut™ Cas9 Protein, enable the generation, expansion, and processing of large numbers of functionally viable human CAR NK cells.

We will present data demonstrating successful engineering of CAR NK cells at clinical scale as measured by knock-out efficiency, anti-Meso3 knock-in, post-editing phenotype, viability, expansion over 3 weeks, and functionality shown by cytotoxicity in a cancer cell model.

Attend this webinar to discover:

  • The potential of genetically modified NK cells in a clinical cell therapy setting
  • Expected post-electroporation viability, phenotypic profile, proliferation ability, and cytotoxic effects of CAR NK cells in a typical gene editing workflow
  • Available GMP-compliant tools to support genetic modification, processing, and expansion of primary human NK cells
Deepak Kumar
Deepak Kumar
Scientist III, Thermo Fisher Scientific

Deepak Kumar, Ph.D. is a scientist III at Thermo Fisher Scientific where he focuses on NK cell gene editing using viral and non-viral approaches to support cell and gene therapy workflow applications. Dr. Kumar received his Ph.D. in Molecular Biology and Genetic Engineering from the Institute of Life Sciences (Department of Biotechnology, Government of India), India. After his Ph.D., he joined as Postdoctoral Fellow at Moores Cancer Center, University of California, San Diego and then worked as Project Scientist at the Department of Medicine, University of California, San Diego.

SPEAKERS

Deepak Kumar
Deepak Kumar
Scientist III, Thermo Fisher Scientific

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual
27 June
in 66
Days
Register
Pure and simple: understanding LNP analytics for better mRNA-based drugs

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe
29 May
in 37
Days
Register
Empowering patient care: in-process and quality control solutions for cellular therapies

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz
23 May
in 31
Days
Register
T cells from beginning to end: optimizing leukopak and drug product cryopreservation

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity
22 May
in 30
Days
Register
Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes
21 May
in 29
Days
Register